Back to Search Start Over

Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Authors :
Brooke L. Fridley
Soma Das
Kunle Odunsi
Evelyn Despierre
Robert A. Vierkant
Peixian Chen
Ignace Vergote
Peter H. O'Donnell
Kirsten B. Moysich
Yi Lu
Estrid Høgdall
Diether Lambrechts
Stuart MacGregor
Jonathan Beesley
Jenny Gross
Beth Y. Karlan
Hae Kyung Im
Eric R. Gamazon
Georgia Chenevix-Trench
Shuangli Mi
Anna deFazio
Yarden S. Fraiman
Ellen L. Goode
Shiwei Duan
Wei Zhang
Emily O. Kistner
James Paul
Sharon E. Johnatty
Nancy J. Cox
M. Eileen Dolan
R. Stephanie Huang
Robert S. Brown
Allan Jensen
Dana Ziliak
Susanne K. Kjaer
Matthew Grasela
Source :
Clinical Cancer Research. 17:5490-5500
Publication Year :
2011
Publisher :
American Association for Cancer Research (AACR), 2011.

Abstract

Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy. Experimental Design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide polymorphisms (SNP) associated with cellular sensitivity to carboplatin through their effects on mRNA expression using International HapMap lymphoblastoid cell lines (LCL) and replicated them in additional LCLs. SNPs passing both stages of the cell-based study were tested for association with progression-free survival (PFS) in patients. Phase 1 validation was based on 377 ovarian cancer patients receiving at least four cycles of carboplatin and paclitaxel from the Australian Ovarian Cancer Study (AOCS). Positive associations were then assessed in phase 2 validation analysis of 1,326 patients from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Results: In the initial GWAS, 342 SNPs were associated with carboplatin-induced cytotoxicity, of which 18 unique SNPs were retained after assessing their association with gene expression. One SNP (rs1649942) was replicated in an independent LCL set (Bonferroni adjusted P < 0.05). It was found to be significantly associated with decreased PFS in phase 1 AOCS patients (Pper-allele = 2 × 10−2), with a stronger effect in the subset of women with optimally debulked tumors (Pper-allele = 4 × 10−3). rs1649942 was also associated with poorer overall survival in women with optimally debulked tumors (Pper-allele = 9 × 10−3). However, this SNP was not significant in phase 2 validation analysis with patients from numerous cohorts. Conclusion: This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect. Clin Cancer Res; 17(16); 5490–500. ©2011 AACR.

Details

ISSN :
15573265 and 10780432
Volume :
17
Database :
OpenAIRE
Journal :
Clinical Cancer Research
Accession number :
edsair.doi.dedup.....4d49b2cd83848b7b1b8587b8b27f1d5e
Full Text :
https://doi.org/10.1158/1078-0432.ccr-11-0724